Literature DB >> 25662443

The inflammatory microenvironment in MDS.

Lili Yang1, Yaqin Qian, Erika Eksioglu, Pearlie K Epling-Burnette, Sheng Wei.   

Abstract

Myelodysplastic syndromes (MDS) are a collection of pre-malignancies characterized by impaired proliferation and differentiation of hematopoietic stem cells and a tendency to evolve into leukemia. Among MDS's pathogenic mechanisms are genetic, epigenetic, apoptotic, differentiation, and cytokine milieu abnormalities. Inflammatory changes are a prominent morphologic feature in some cases, with increased populations of plasma cells, mast cells, and lymphocytes in bone marrow aspirates. Accumulating evidence suggests that the bone marrow microenvironment contributes to MDS disease pathology, with microenvironment alterations and abnormality preceding, and facilitating clonal evolution in MDS patients. In this review, we focus on the inflammatory changes involved in the pathology of MDS, with an emphasis on immune dysfunction, stromal microenvironment, and cytokine imbalance in the microenvironment as well as activation of innate immune signaling in MDS patients. A better understanding of the mechanism of MDS pathophysiology will be beneficial to the development of molecular-targeted therapies in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25662443     DOI: 10.1007/s00018-015-1846-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  84 in total

1.  Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.

Authors:  Bart L Scott; Aravind Ramakrishnan; Mark Fosdal; Barry Storer; Pamela Becker; Steve Petersdorf; H Joachim Deeg
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

Review 2.  Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2005-07-27       Impact factor: 6.968

3.  Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.

Authors:  Zhi-Gang Zhao; Wen Xu; Hai-Peng Yu; Bing-Ling Fang; Shu-Hong Wu; Fang Li; Wei-Min Li; Qiu-Bai Li; Zhi-Chao Chen; Ping Zou
Journal:  Cancer Lett       Date:  2011-10-15       Impact factor: 8.679

4.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

Review 5.  Normal stem cells and cancer stem cells: the niche matters.

Authors:  Linheng Li; William B Neaves
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

Authors:  H Joachim Deeg; Peter Y Z Jiang; Leona A Holmberg; Bart Scott; Effie W Petersdorf; Frederick R Appelbaum
Journal:  Leuk Res       Date:  2004-11       Impact factor: 3.156

Review 7.  The role of the immune system in myelodysplasia: implications for therapy.

Authors:  Elaine M Sloand; Katayoun Rezvani
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

8.  Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors:  Tony Navas; Li Zhou; Myka Estes; Edwin Haghnazari; Aaron N Nguyen; Yongkai Mo; Perry Pahanish; Mani Mohindru; Tim Cao; Linda S Higgins; Leonidas C Platanias; Alan List; Amit Verma; T Bhagat; S Gajavelli; S Kambhampati
Journal:  Leuk Lymphoma       Date:  2008-10

9.  Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes.

Authors:  Adam W Mailloux; Pearlie K Epling-Burnette
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

10.  Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.

Authors:  Irene Gañán-Gómez; Yue Wei; Hui Yang; Sherry Pierce; Carlos Bueso-Ramos; George Calin; María Del Carmen Boyano-Adánez; Guillermo García-Manero
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more
  23 in total

1.  Constitutive Activation of NIK Impairs the Self-Renewal of Hematopoietic Stem/Progenitor Cells and Induces Bone Marrow Failure.

Authors:  Yan Xiu; Wingel Y Xue; Allyn Lambertz; Mariah Leidinger; Katherine Gibson-Corley; Chen Zhao
Journal:  Stem Cells       Date:  2016-11-02       Impact factor: 6.277

Review 2.  Deconstructing innate immune signaling in myelodysplastic syndromes.

Authors:  Madeline Niederkorn; Molly Smith; Laura Barreyro; Melinda E Varney; Katelyn Melgar; Daniel T Starczynowski
Journal:  Exp Hematol       Date:  2015-07-02       Impact factor: 3.084

3.  Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.

Authors:  Anacélia Matos; Silvia M M Magalhães; Michael J Rauh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Clonality in context: hematopoietic clones in their marrow environment.

Authors:  James N Cooper; Neal S Young
Journal:  Blood       Date:  2017-10-18       Impact factor: 22.113

5.  Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome.

Authors:  Anacélia Gomes de Matos; Howard Lopes Ribeiro Junior; Daniela de Paula Borges; Bruno Memória Okubo; Juliana Cordeiro de Sousa; Maritza Cavalcante Barbosa; Marilena Facundo de Castro; Romélia Pinheiro Gonçalves; Ronald Feitosa Pinheiro; Silvia Maria Meira Magalhães
Journal:  Med Oncol       Date:  2017-08-30       Impact factor: 3.064

Review 6.  Biology of the bone marrow microenvironment and myelodysplastic syndromes.

Authors:  Erinn B Rankin; Anupama Narla; Joseph K Park; Shuo Lin; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2015-07-20       Impact factor: 4.797

Review 7.  Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance.

Authors:  Thomas Clapes; Stylianos Lefkopoulos; Eirini Trompouki
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

Review 8.  The Role of Toll-Like Receptors in Hematopoietic Malignancies.

Authors:  Darlene A Monlish; Sima T Bhatt; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

9.  De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.

Authors:  Matheus Rodrigues Lopes; João Kleber Novais Pereira; Paula de Melo Campos; João Agostinho Machado-Neto; Fabiola Traina; Sara T Olalla Saad; Patricia Favaro
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 10.  Immune Mechanisms in Myelodysplastic Syndrome.

Authors:  Andreas Glenthøj; Andreas Due Ørskov; Jakob Werner Hansen; Sine Reker Hadrup; Casey O'Connell; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.